IMMUNOLOGY2026™ Conference Recordings For Attendees-SP2H selectively depletes Stimulator of Interferon Genes (STING), reducing inflammation and improving survival in Trex1-/- mice

SP2H selectively depletes Stimulator of Interferon Genes (STING), reducing inflammation and improving survival in Trex1-/- mice

Back to course

Video Transcription

Video Summary

The speaker presents SB2H, a highly selective STING degrader designed to eliminate STING rather than merely inhibit it. STING drives inflammation in interferonopathies, autoimmune disease, and some metabolic disorders, but existing inhibitors are weak or nonselective. SB2H rapidly and potently depletes STING in human cells, patient fibroblasts, and PBMCs, with minimal off-target effects and good safety. In mice, it shows favorable pharmacokinetics, suppresses STING-driven cytokines, reduces inflammation, improves survival in Trex1 knockout mice, and improves disease in a SAVI model. The compound is now being evaluated for clinical development in STING-related inflammatory and fibrotic diseases.

Meta Tag

Date April 16, 2026 8:15 AM - 8:30 AM

Room 156

Session Targeting B Cells and Innate Immune Functions in Autoimmunity

Speaker Richard Bethell

Track Therapeutic Approaches to Autoimmunity (THER)

Year 2026

Keywords

SB2H

STING degrader

interferonopathies

autoimmune inflammation

Trex1 knockout mice

April 16, 2026 8:15 AM - 8:30 AM

156

Targeting B Cells and Innate Immune Functions in Autoimmunity

Richard Bethell

Therapeutic Approaches to Autoimmunity (THER)

2026